替罗非班在急性心肌梗死介入治疗中的疗效

Effect of Tirofiban on Patients with Acute Myocardial Infarction During PCI

目的:研究ST段抬高型急性心肌梗死(AMI)患者在急诊行经皮冠状动脉介入术(PCI)中应用替罗非班的有效性和安全性。方法:患者80名,随机分为试验组(替罗非班+PCI组)40例,对照组(PCI组)40例。观察PCI术前、术后梗死相关动脉(IRA)TIMI血流情况以及患者7d内两组患者心血管事件(MACE)的发生率,及术后两组患者的出血发生率。结果:介入术后造影显示替罗非班组患者恢复TIMI 3级血流比例明显高于对照组。住院期间替罗非班组心血管事件发生率较对照组低(P<0.05)。而两组间术后出血比例差异无统计学意义。结论:ST段抬高型急性心肌梗死(AMI)患者在急诊冠状动脉介入术中使用血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班是有效并且安全的,其疗效优于常规治疗组。

Objective ： To investigate the efficacy and safety of tirofiban on patients with acute myocardial infarction （AMI） during emergency PCI. Method： 80 patients with PCI were randomized into a study group （tirofiban ＋ PCI group, n = 40） and a controlled group （PCI group n = 40）. Their angiographic characteristics before and after PCI were collected and studied. The in-hospital cardiovascular events and the bleeding complications were assessed. Result： The patients in the study group were recovered with a higher rate of TIMI 3 grade flow than in the controlled group. There was a lower incidence of the in-hospital cardiac events in the study group than that of the control group （P 〈 0.05）. There were no differences between the two groups in the incidence of bleeding. Conclusion ： Tirofiban is effective and safe for patients with STEMI during emergency PCI.